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Abstract: The aim of this study was to compare the effect of
implantation site (i.e., subcutaneous, SQ vs. intramuscular,
IM) on bone forming capacity of cell-based and growth
factor-based scaffolds in athymic nude rats after an implanta-
tion period of 8 weeks. Cell-based scaffolds consisted of
porous hydroxyapatite/tricalcium phosphate (HA/TCP) scaf-
folds seeded with either human adipose tissue-derived mes-
enchymal stem cells (AT-MSCs) only or both AT-MSCs and
human umbilical vein endothelial cells (HUVECs), which were
precultured in osteogenic medium for 7 days. Growth factor-
based scaffolds consisted of porous HA/TCP scaffolds with 20
mg preadsorbed bone morphogenetic protein-2 (BMP-2). His-
tological and histomorphometrical analysis were used to
assess bone formation. A differentiation experiment was per-
formed in parallel to compare the in vitro osteogenic capacity
of cell-based scaffolds. The results showed that cell-based
scaffolds showed evident osteogenic differentiation in vitro,
with only marginal differences between AT-MSCs only and
AT-MSCs/HUVECs. In vivo, none of the cell-based scaffolds
showed bone formation, irrespective of the site of implanta-
tion. In contrast, all growth factor-based scaffolds showed
bone formation at both implantation sites without differences
in the amount of formed bone. In conclusion, the results of
this study demonstrated that the bone forming capacity of
HA/TCP scaffolds with pre-adsorbed BMP-2 was equal at dif-
ferent ectopic implantation sites. Further, despite obvious in
vitro osteogenic differentiation of AT-MSCs and AT-MSCS/
HUVECs on HA/TCP scaffolds, no bone formation of these
cell-based scaffolds was observed in vivo. This indicates fur-
ther investigation on bone formation mechanisms of AT-
MSCs is needed before AT-MSCs can be used as a cytothera-
peutic treatment in clinics. VC 2014 Wiley Periodicals, Inc. J Biomed
Mater Res Part A: 103A: 439–450, 2015.
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INTRODUCTION
The worldwide incidence (i.e., 2.2 million annually1) of bone
disorders and bone defects has increased substantially and
is expected to double by 2020.2 The potential of bone
regeneration strategies becomes especially challenging
under compromised conditions, such as patients with medi-
cally compromised conditions (e.g., osteoporosis, diabetes,
and cancer), or in case of critical size bone defects and
bone defects cannot heal spontaneously.2 The gold standard
of current therapeutic strategies is autologous bone grafts.
However, the limitation in bone amount to be harvested and
donor site morbidity (e.g., pain and infection) are disadvan-
tageous for the clinical use of autologous bone grafts. The
use of allografts can avoid these disadvantages, but is
Correspondence to: Jeroen JJP van den Beucken; e-mail: jeroen.vandenbeucken@radboudumc.nl
Contract grant sponsor: Royal Netherlands Academy of Arts and Sciences; contract grant number: KNAW, 08-PSA-M-02
Contract grant sponsor: National 973 project of China
Contract grant sponsor: 2011CB606205
VC 2014 WILEY PERIODICALS, INC. 439
associated with risks of disease transmission or immuno-
genic rejection.3 Bone tissue engineering and regenerative
medicine (BTE/RM), using constructs based on combina-
tions of scaffolds, cells, and growth factors are considered
as a promising alternative approach to repair bone defects.
Bone morphogenetic protein 2 (BMP-2) is the most
extensively studied osteoinductive factor4 and is currently
available via recombinant technology-based production
methods. Recombinant human (rh)BMP-2 has been widely
used as a component in several commercially available bone
regenerative products (e.g., InfuseVR and AmplifyTM Matrix),
which have received FDA-approval for several clinical appli-
cations, such as spinal fusion,5 treatments of cleft lip and
palate,6 and maxillofacial bone defects.7,8
Mesenchymal stem cells (MSCs) represent the high
potential cell type for bone regeneration9 as a result of the
multipotential differentiation capacity including differentia-
tion into the osteogenic lineage.10 Despite of the exciting
outcomes in animal studies, in which bone regeneration was
demonstrated using human MSCs,11,12 the application of
human MSCs in a clinical setting is far behind. Since mid
2012, there is only one approved stem cell product on the
market in the United States (HemacordVR , i.e., hematopoietic
progenitor cells from cord blood for patients with disorders
affecting the hematopoietic system) and only one approved
stem cell drug in Canada (ProchymalVR , i.e. a stem cell ther-
apy based on allogenic MSCs to treat acute graft-vs.-host
disease).13 To date, no stem cell-based product is available
for bone regeneration, although both clinical trials and few
unlicensed human MSCs treatments have been carried
out.14 For bone regeneration in clinical applications, beyond
the safety and efﬁcacy aspects, vascularization plays an
essential role. Insufﬁcient vascularization caused by the
slow rate (<1 mm/day) of blood vessel inﬁltration into the
tissue-engineered constructs hampers cell survival and suc-
cessful integration of the graft.15 Coculture of MSCs with
endothelial (progenitor) cells (ECs) has attracted most
attention in strategies that seek rapid vascularisation.16 Sur-
prisingly, such cocultures are demonstrated to induce higher
in vitro mineralization17 and more in vivo bone forma-
tion18,19 compared with MSCs monocultures, but no clinical
data are available yet. Adipose tissue-derived MSCs (AT-
MSCs) were explored within the last decade20 due to the
easy handling in cell harvesting and high cell yields
reviewed previously.21,22 Limited data are available on
cocultures using AT-MSCs in combination with ECs.
The apparent unsatisfactory bone regenerative capacity
of human MSCs in clinics leads to an interest in analyzing
the potential causative mechanisms. The earlier mentioned
lack of vascular supply and related cell death after implan-
tation,23 is suggested to be a major cause of failure of BTE/
RM in patients.24 From this, it is straightforward to assume
that different implantation sites, which differ in blood ﬂow
and thereby oxygen, nutrition supply, and waste products
removal,25 inﬂuence the bone forming capacity of BTE/RM
constructs. Experimentally, ectopic implantation models
have been used tremendously for the evaluation of osteoin-
ductive scaffolds, bone-forming stem cells, and growth fac-
tors. Subcutaneous (SQ) and intramuscular (IM)
implantation are the two mainly used ectopic models, for
which vascularization (IM> SQ) has been regarded as the
predominant difference.25
The aim of this study was to compare the effect of
implantation site (i.e., SQ vs. IM) on the bone forming
capacity of cell- and growth factor-based constructs in athy-
mic nude rats after 8 weeks implantation. We hypothesized
that IM implantation would induce higher amounts of bone
formation compared with SQ implantation, irrespective of
the scaffolds used, owing to an increased vascularization in
muscle tissue compared with SQ connective tissue. Porous
hydroxyapatite/tricalcium phosphate (HA/TCP) was used as
a scaffold, with either precultured (7 days in osteogenic
medium) AT-MSCs or AT-MSCs/human umbilical vein ECs
(HUVECs) to generate cell-based constructs or preadsorbed
BMP-2 (20 mg/scaffold) to generate growth factor-based
constructs. Histological and histomorphometrical analysis
were used to assess bone formation. A differentiation
experiment was performed in parallel to compare in vitro
the osteogenic capacity of cell-based constructs.
MATERIALS AND METHODS
Experimental set-up
The experimental set-up is schematically represented in Fig-
ure 1. An in vitro parallel study was used to compare the
osteogenic capacity of AT-MSCs and AT-MSCs/HUVECs cul-
tured on HA/TCP scaffolds. To further compare the bone
forming capacity in the two implantation sites (SQ and IM),
HA/TCP scaffolds combined with either cells (AT-MSCs or
AT-MSCs/HUVECs) or growth factor (BMP-2) were implanted
in athymic nude rats for 8 weeks and bone formation was
assessed histologically and histomorphometrically.
Cell isolation and culture
Human subcutaneous adipose tissue from the abdomen was
obtained from waste material from the Department of Plas-
tic Surgery (Tergooi Hospital, Hilversum, the Netherlands)
after written informed consent. This study complied with
the principles of the Declaration of Helsinki.
FIGURE 1. Schematic representation of the experimental design. SQ,
subcutaneous; IM, intramuscular. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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AT-MSCs isolation was performed according to a previ-
ously described protocol.26 Brieﬂy, resected tissue was
minced using surgical scalpel and scissor and digested with
0.1% collagenase A (Roche Diagnostics GmbH, Mannheim,
Germany) in phosphate-buffered saline (PBS; B. Braun, Mel-
sungen, Germany) containing 1% bovine serum albumin
(BSA; Roche Diagnostics) at 37C for 45 min with shaking.
The digested tissue was centrifuged (600g) for 10 min and
the cell pellet was resuspended in 5 mL of PBS/1% BSA and
ﬁltered with a 200 mm mesh (Roche Diagnostics). Cells were
then subjected to a Ficoll density centrifugation step to
remove erythrocytes and were plated at a density of 100,000
cells/cm2. Proliferation medium was used for cell expansion,
in which human platelet lysate (PL) was supplemented (PM,
see Table I) because PL-supplementation in medium has been
proved to be optimal for AT-MSCs culture.27 AT-MSCs from 1
donor (female, 38 years old) from passage 4 were used in the
experiment. These cells have been conﬁrmed to mineralize in
vitro according to our previous study.27
HUVECs were obtained from a commercial source (Bec-
ton Dickinson Biosciences, BD; Breda, the Netherlands) and
cultured in endothelial cell culture medium (EM, see Table
I) according to instructions from BD. Cells from passage 7
were used in the experiment.
Scaffold preparation and cell seeding
Porous cubic biphasic 75% HA/ 25 % b-TCP ceramic scaf-
folds (CamceramVR ; 3 3 3 3 3 mm3; CAM Bioceramics BV,
Leiden, the Netherlands) with a volumetric porosity of
75%, and a pore diameter ranging from 100 to 500 mm
were used in this study. The scaffolds were sterilized by
autoclaving and prewetted in 50% fetal bovine serum (in
alpha minimum essential medium) overnight before cell
seeding. A total of 30 scaffolds were put into a 20-mL
syringe (BD Plastipak), in which 10 mL of osteogenic
medium (OM, see Table I) containing a total number of 30
3 106 cells (AT-MSCs or AT-MSCs/HUVECs (50 : 50) was
included. AT-MSCs and HUVECs were seeded at a ratio of 50
: 50 (previously demonstrated optimal for osteogenesis28).
Cells were seeded by rotating at a speed of 12 rpm at 37C
in a humid atmosphere for 3 h. Next, the cell-based scaf-
folds were transferred from the syringe into nonadhesive
25-well square plates (Greiner Bio-one). The unattached
cells from the syringe were resuspended into OM, divided,
and dripped onto each scaffold (50 mL) and the scaffolds
were incubated for another hour. Subsequently, 1.5 mL of
OM was added to each well and the cell-based scaffolds
were cultured at 37C in a humid atmosphere in OM for 7
days, with medium refreshment twice. Thereafter, the cell-
based scaffolds were randomly assigned to enrollment in in
vitro and in vivo experiments. For in vitro experiments, scaf-
folds were collected on different time points (days 7, 14,
and 21) for evaluation of cell morphology, proliferation and
differentiation. For in vivo experiments, both cell-based and
growth factor-based scaffolds were used. For preparation of
growth factor-based scaffolds, 30 mL of BMP-2 (InductOsVR ,
London, UK) solution (containing 20 lg BMP-2 in 30 lL of
PBS) was dripped onto each scaffold in sterilized nonadhe-
sive 25-well plates and allowed to adsorb for 2 h.
In vitro performance of cell-based scaffolds
To analyze cell proliferation and osteogenic differentiation
of the seeded cells, an in vitro study was performed (n53),
including the following three groups:
• HA/TCP (no cells);
TABLE I. Cell Culture Media Used in the Study
Abbreviated Name Full Name Constituents Origin of Constituents
PM Proliferation medium a-MEM Gibco-BRL
5% PL VU University Medical Centre
100 U/mL penicillin and 10 lg/
mL streptomycin
Gibco-BRL
10 U/mL heparin LEO Pharma
OM Osteogenic medium a-MEM Gibco-BRL
5% PL VU University Medical Centre
100 U/mL penicillin and 10 lg/
mL streptomycin
Gibco-BRL
0.2 mM L-ascorbic acid-2-phosphate Sigma
2 mM L-glutamine Gibco-BRL
1028 M dexamethasone Sigma
0.01M b-glycerophosphate Sigma
10 U/mL heparin LEO Pharma
EM Endothelial cell culture medium basal Medium 200 2% FBS, 10
ng/mL epidermal growth fac-
tor, 3 ng/mL basic fibroblast
growth factor, 10 mg/mL hep-
arin, 0.2 lg/mL bovine serum
albumin, 1 mg/mL hydrocorti-
sone, and 0.2% gentamicin/
amphotericin B
Invitrogen
a-MEM, minimal essential medium; PL, human platelet lysate; FBS, fetal bovine serum.
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• Mo (HA/TCP scaffolds seeded with AT-MSCs -
monoculture);
• Co (HA/TCP scaffolds seeded with AT-MSCs/HUVECs -
coculture).
Methylene blue staining
On day 1, scaffolds were stained with methylene blue (MB)
to observe cell distribution on the surface. The staining
method used was slightly modiﬁed according to the web
protocol.29 Brieﬂy, scaffolds were washed with PBS three
times and then 1% MB (Merck, Darmstadt, Germany) solu-
tion was added to each scaffold at room temperature for 5
min. Afterwards, the scaffolds were washed thoroughly with
PBS until no residual color could be washed out. The scaf-
folds were maintained in PBS and imaged using a stereomi-
croscope (Leica MZ12, Rijswijk, the Netherlands) equipped
with a Leica camera (Leica DC200, Rijswijk, the
Netherlands).
Methylene blue/basic fuchsin staining and scanning
electron microscopy
In order to observe cell morphology on day 7 (time point of
parallel in vivo implantation), MB/basic fuchsin (BF) stain-
ing as well as scanning electron microscopy (SEM) analysis
were performed. For MB/BF staining, scaffolds (n5 3) were
washed with PBS and ﬁxed in 10% neutral formalin for 2 h.
After ﬁxation, the scaffolds were dehydrated in a graded
series of ethanol and embedded in methylmethacrylate.
Thin sections (10 mm; 3 per scaffold) were prepared using a
histological diamond saw (Leica Microsystems SP 1600,
Nussloch, Germany) and stained with 1% MB and 0.3% BF.
For SEM analysis, scaffolds were rinsed with ﬁltered
PBS, and ﬁxed in 2% glutaraldehyde for 2 h. Then, the scaf-
folds (n5 3) were washed with 0.1M sodium-cacodylate for
30 min, dehydrated in a graded series of ethanol, and dried
with tetramethylsilane (Merck, Frankfurt, Germany). Exami-
nations from both peripheral and cross-sections of the scaf-
folds were performed using a SEM (JEOL 6340F, Peabody,
USA) after deposition of a sputter-coated gold layer.
DNA content and alkaline phosphatase activity
DNA content and alkaline phosphatase (ALP)-activity (extra-
and intracellular ALP-activity separately) were assessed for
evaluation of cell proliferation and osteogenic differentiation,
respectively, at multiple time points (days 7, 14, and 21). First,
medium from each scaffold (bare HA/TCP and cell-based scaf-
folds) was collected for extracellular ALP-activity measure-
ments. For sampling, scaffolds (n5 3) were cultured in a
precise volume of medium (1.5 mL) and collected at indicated
time points during medium refreshment. The medium was
stored at 280C until the measurement. After medium collec-
tion, the same scaffolds were used for sampling of DNA con-
tent and intracellular ALP-activity samples via rinsing with
PBS, addition of 1 mL of MilliQ per scaffold, and two freeze-
thaw cycles (280C  37C) before biochemical analysis.
Both DNA content and ALP-activity assays were carried
out according to previously described methods.17 DNA con-
tent was measured using Quant-iT
TM
Picogreen Kit (Invitro-
gen; Breda, the Netherlands) and ALP-activity was
determined using an ALP assay kit (p-nitrophenyl phos-
phate, pNPP; Sigma-Aldrich, the Netherlands). Values of the
ALP-activity in cell-seeded scaffolds were corrected by sub-
tracting the values from HA/TCP scaffolds without cells to
exclude the effects of bare scaffolds.
In vivo experiment design
Nine healthy 6-weeks old male athymic nude rats (weight
150–200 g; Crl:NIH-Foxn1rnu, Charles River) were used
according to national guidelines for the use and care of lab-
oratory animals and after ethical approval by the Animal
Ethical Committee (RU-DEC 2012-013).
After in vitro pre-culture for 7 days, cell-based con-
structs were randomly distributed for implantation either at
SQ or IM sites. Three groups were deﬁned for each implan-
tation site, with six scaffolds for each group (n5 6):
• Mo (HA/TCP scaffold seeded with AT-MSCs -
monoculture);
• Co (HA/TCP scaffold seeded with AT-MSCs/HUVECs -
coculture);
• BMP-2 (HA/TCP scaffold loaded with BMP-2).
Surgical procedure
For surgery, the animals were premedicated by subcutane-
ous injection of carprofen (5 mg/kg; RimadylVR , Pﬁzer Ani-
mal Health B.V., Capelle aan de IJssel, Netherlands) to
reduce operative pain. Surgery was performed under gen-
eral anesthesia with nitrous oxide, oxygen, and isoﬂurane.
For SQ implantation, the animals were immobilized and
placed in a ventral position. The back of the animals was
shaved and disinfected with povidone-iodine. A longitudinal
incision was made on each side of the vertebral column. A
subcutaneous pocket was created using blunt dissection.




For IM implantation in the adductor thigh muscle, the
animals were placed in a dorsal position. The groin and leg
area were shaved, disinfected with povidone-iodine, and a
longitudinal incision was made in the thigh. The incision
was through the fascia and a pocket was made in the
adductor thigh muscle. After the scaffolds were placed into
the pockets, the soft tissues were closed in two layers with
5-0 and 4-0 VicrylV
R
resorbable sutures.
Each animal received four constructs in total (2 con-
structs for SQ implantation and 2 constructs for IM implanta-
tion, with 1 construct per pocket in each lateral side. After
surgery, subcutaneous injections of carprofen (5 mg/kg;
RimadylV
R
) were given for 2 days to reduce postoperative
pain.
Explantation and micro-computed tomography
Eight weeks after implantation, animals were euthanised
using CO2 suffocation. The specimens with the surrounding
tissue were retrieved. Next, the specimens were ﬁxed in
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10% neutral formalin for 24 h and transferred into 70%
ethanol for micro-computed tomography (micro-CT) scan-
ning. Two specimens (n5 2) randomly selected from each
group were used for micro-CT imaging. The specimens were
imaged using a high resolution SkyScan-1172 micro-CT
imaging system (SkyScan, Aartselaar, Belgium). Next, cone
beam reconstruction was performed on the projected ﬁles
using Nrecon V1.5 (SkyScan, Kontich, Belgium). Finally, a
3D-reconstruction of the specimens was obtained by using
3D creator software as previously described.30 The porosity
of each specimen was analyzed using Bruker-CT-Analyser
software (Coventry, UK). In brief, a volume of interest (VOI)
with a cubic volume of interest of 8 mm3 was selected from
the center of each specimen from the 3D-reconstructed
image. A threshold (61 for x-axis and 255 for y-axis, repre-
sent gray value of scaffold and mineralized tissue and its
density, respectively) of gray values was selected and the
values above and below this value were regarded separately
as: material and mineralized tissue; void and soft tissue. It
is not possible to distinguish mineralized tissue/bone from
the HA/TCP material. The pore volume was determined by
subtracting the volume of the former part (i.e., material and
mineralized tissue) from the total VOI. Thereafter, the poros-
ity volume percentage for each specimen was calculated by
dividing the porosity volume (mm3) by the total VOI (mm3).
Histological and histomorphometrical evaluation
After ﬁxation, the specimens were dehydrated in a graded
series of ethanol and embedded in methylmethacrylate.
Thin sections (10 mm; 3 per specimen) were prepared using
a histological diamond saw (Leica) and stained with MB/BF.
All histological sections were photographed with the
Zeiss Imager Z1 microscope equipped with the AxioCam
MRc5 camera using AxioVision 4.8 software (Carl Zeiss
Microimaging GmbH, G€ottingen, Germany). By using the
Mosaic function of AxioVision 4.8 software, high resolution
images of each full sized section could be obtained. Three
sections were made per specimen and these 3 sections per
specimen were analyzed. The incidence of bone formation
for each group was analyzed. Furthermore, histomorpho-
metrical evaluation was performed to quantify bone forma-
tion within the three experimental groups (Mo, Co, and
BMP-2) in both SQ and IM sites according as described pre-
viously.31 In brief, histological sections were scored using
computer-based image analysis techniques (LeicaV
R
Qwin
Proimage analysis system, Wetzlar, Germany), which recog-
nize bone tissue from the others (e.g., HA/TCP scaffolds,
pores and soft tissues) based on different RGB values from
magniﬁed digitalized images (1003). Manual corrections
based on morphological appearance were applied to ensure
adequate selection of newly formed bone tissue within the
selected area. A region of interest (ROI) was deﬁned by
selecting the area within ﬁbrous tissue capsule. The param-
eters for evaluating bone amount as listed below were
measured:
• BA/PA (%): bone area (mm2)/pore area (mm2);
• BA/ROI (%): bone area (mm2)/region of interest
(mm2, i.e., the scaffold area).
Statistical analysis
Data were expressed as mean6 standard deviation. Graph-
pad Instat software (InstatV
R
3.05, Graphpad Software, La
Jolla, USA) was used for statistical analysis. For the statisti-
cal analysis for DNA content and ALP-activity in vitro
(n5 3), an independent t-test was performed to compare
between Mo and Co and a one-way ANOVA with posthoc
Tukey HSD test was applied for the comparison among dif-
ferent time points (days 7, 14, and 21). For the comparison
of bone formation in SQ and IM sites in vivo (n56), a
paired t-test was performed. p< 0.05 was deﬁned as statis-
tically signiﬁcant.
RESULTS
Microscopic observation for cell-based scaffolds in vitro
MB staining (Fig. 2) on day 1 showed an apparent differ-
ence between bare HA/TCP scaffolds [Fig. 2(A)] and the
FIGURE 2. Microscopic observation using methylene blue staining on HA/TCP on day 1 in vitro (n53). (A) bare HA/TCP scaffold and (B) cell-
seeded scaffold (from AT-MSCs seeded HA/TCP, Mo). Arrow indicates cells. [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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cell-based constructs [Fig. 2(B), representative image from
Mo], for which the latter clearly demonstrated positively
stained cell nuclei. The same trend was observed for Mo
and Co, for which a representative image from Mo is shown.
On day 7, microscopic observation including both MB/BF
staining and SEM was performed to observe the cell mor-
phology for the cell-based constructs. MB/BF staining
showed that cells penetrated inside the pores [Fig. 3(A)],
FIGURE 3. Microscopic observation of cell morphology on HA/TCP on day 7 in vitro (n5 3). A: representative image of methylene blue/basic
fuchsin staining for cell-seeded scaffolds (from AT-MSCs/HUVECs seeded HA/TCP, Co). B: Magnified image of the insert in (A). C–H: Represent
scanning electron microscopy images of both peripheral (C,E,G) and cross-sections (D,F,H) for bare HA/TCP, Mo, and Co, respectively. Arrows
indicate cell layer. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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and at higher magniﬁcation, cell nuclei were clearly
observed [Fig. 3(B)]. The structure of the bare HA/TCP scaf-
folds was shown from both peripheral [Fig. 3(C)] and cross-
sections [Fig. 3(D)] using SEM analysis. SEM images demon-
strated cell distribution on the surface [Fig. 3(E,G)] as well
as cell ingrowth into the centre of the constructs [Fig.
3(F,H)] for both Mo [Fig. 3(E,F)] and Co [Fig. 3(G,H)]. Cells
clearly covered the surface of the constructs, whereas cross-
sections displayed the presence of cells throughout the
porous structure of the constructs.
In vitro performance of cell-based scaffolds
DNA content, as an index for cell proliferation, is displayed in
Figure 4(A). No signiﬁcant difference was observed between
Mo and Co at any time point. Additionally, Mo and Co con-
structs showed a rather constant DNA content over time.
Both the extra- and intracellular ALP-activity were ana-
lyzed and the results are shown in Figure 4(B,C). For extrac-
ellular ALP-activity [Fig. 4(B)], no signiﬁcant differences
were found between Mo and Co at individual time points or
over time (p> 0.05), although a tendency toward higher
ALP-activity for Mo constructs was apparent. For intracellu-
lar ALP-activity [Fig. 4(C)], signiﬁcantly higher values were
found for Mo constructs compared with Co constructs on
day 7 (p< 0.01), while similar values were observed for Mo
and Co on days 14 and 21. Analogous to extracellular ALP-
activity results, intracellular ALP-activity showed a tendency
toward higher ALP-activity for Mo constructs. Comparison
among different time points demonstrated that intracellular
ALP-activity increased over time for both Mo and Co con-
structs, showing signiﬁcantly higher values on day 21 than
on day 7 and day 14.
In vivo experiment
General observations. All animals recovered uneventfully
from the surgery and no infections or complications were
observed during the 8 week implantation period. All speci-
mens (n56 per group) were retrieved and during retrieval,
no macroscopic signs of inﬂammation or adverse tissue
response were observed at the implantation sites. Obvious
soft tissue encapsulation was observed for all constructs at
all implantation sites.
Micro-computed tomography. A 3D reconstruction was
generated using micro-CT and the porosity of the constructs
was determined [Fig. 5]. The 3D reconstructions showed
porous structures of the constructs, with large similarity for
constructs from both implantation sites. The dimension and
the number of the pores showed an apparent decrease for
growth factor-based constructs compared with both original
bare scaffolds and cell-based constructs. The porosity of the
bare scaffolds (n52) was 67.06 11.0%. The average values
of porosity for the two randomly selected specimens in each
group showed a decrease in the BMP-2 group (33.46 3.9%
in SQ and 37.46 3.4% in IM) compared with Mo
(49.06 19.0% in SQ and 56.56 26.1% in IM) and Co con-
structs (58.26 0.1% in SQ and 66.56 6.6% in IM), which
showed a comparable porosity.
Descriptive histology. Histological images for sections of SQ
and IM implantation are presented in Figures 6 and 7,
respectively. Similar results were observed for SQ and IM
implantation sites. In general, none of the specimens
FIGURE 4. Cell proliferation and osteogenic differentiation on HA/TCP
in vitro (n5 3). (A) DNA content; (B) extracellular ALP-activity (from
cell culture medium); (C) intracellular ALP-activity (from cell lysis).
**p< 0.01, indicates significant difference between Mo and Co;
#p< 0.05; ##p< 0.01, indicate significant difference on day 7 vs. day
21 or day 14 vs. day 21. Mo, AT-MSCs seeded HA/TCP; Co, AT-MSCs/
HUVECs seeded HA/TCP. [Color figure can be viewed in the online
issue, which is available at wileyonlinelibrary.com.]
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showed the presence of an inﬂammatory response and soft
tissues (i.e., layers of ﬁbrous cells) ﬁrmly encapsulated the
implanted scaffolds. For Mo and Co constructs, the porous
structure of the scaffolds was ﬁlled with ﬁbrous tissues. In
contrast, growth factor-based constructs showed large
amounts of bone tissue present, predominantly at the con-
cave areas of the pores. Moreover, bone formation was
observed both on the periphery and in the centre of the
constructs and bone marrow-like tissue was observed inside
the pores of the scaffold. At higher magniﬁcation [Figs. 6
and 7], osteocyte-like cells were clearly visible within the
newly formed bone tissue. Additionally, vessel-like struc-
tures, with different shape and size, were frequently
observed for all the groups. However, blood cells were sel-
dom found which might be due to the saw procedure.
Bone forming incidence. Bone formation was observed in
none of the specimens (0/6) for both Mo and Co constructs,
while all of the specimens (6/6) of the growth factor-based
constructs showed the presence of bone tissue, irrespective
of implantation site.
Histomorphometry. Histomorphometrical evaluation of
bone formation for growth factor-based constructs at both
SQ and IM sites was performed, for which the results are
displayed in Figure 8. The percentage of BA/PA at SQ and
IM sites was similar (356 8% and 3364%, respectively).
Similarly, the percentage of BA/ROI at SQ and IM sites was
comparable (2065% and 1963%, respectively).
DISCUSSION
The aim of this study was to compare the effect of implanta-
tion site on the bone forming capacity of cell-based or
growth factor-based constructs in athymic nude rats after
an implantation period of 8 weeks. It was hypothesized that
IM implantation would induce more bone formation in com-
parison to SQ implantation due to more pronounced vascu-
larization in IM site. Porous HA/TCP scaffolds were either
seeded with AT-MSC monocultures or AT-MSC/HUVEC cocul-
tures and precultured in vitro for 7 days or preloaded with
BMP-2, after which the constructs were implanted. Histolog-
ical and histomorphometrical analyses were used to assess
bone formation. An in vitro parallel experiment was
FIGURE 5. Micro-CT 3D reconstructions for Mo, Co, and BMP-2 scaf-
folds after 8 weeks in vivo implantation (n5 2). Mo, AT-MSCs seeded
HA/TCP; Co, AT-MSCs/HUVECs seeded HA/TCP; BMP-2, BMP-2 loaded
HA/TCP; SQ, subcutaneous; IM, intramuscular. [Color figure can be
viewed in the online issue, which is available at wileyonlinelibrary.
com.]
FIGURE 6. Histological images from methylene blue/basic fuchsin
stained sections after 8 weeks subcutaneous (SQ) implantation in vivo
(n56). Bone marrow structures are only observed in the BMP-2
group, which is also the only group with bone formation.
Black arrows indicate vessel-like structures and white arrows indicate
osteocyte-like cells. Mo, AT-MSCs seeded HA/TCP; Co, AT-MSCs/HU-
VECs seeded HA/TCP; BMP-2, BMP-2 loaded HA/TCP. [Color figure
can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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performed to comparatively evaluate the proliferation and
osteogenic differentiation capacity of cell-based constructs.
In general, cells from in vitro cultures showed osteogenic
differentiation with a slightly increased ALP-activity for
monocultures compared with cocultures. In vivo experi-
ments demonstrated that only growth factor-based con-
structs induced bone formation without signiﬁcant
implantation site dependent differences in the amount of
formed bone.
So far, MSCs derived from either mouse32 or rat33,34
have been combined with various scaffolds and no differ-
ence in bone formation was observed in SQ and IM sites.
Nevertheless, research is missing on such comparison using
human MSCs, which behave differently with those from
other animal species.35 Besides, growth factor-based (i.e.,
BMP-2) bone formation in SQ and IM sites was compared as
well since BMP-2 induce bone formation through the
recruitment and stimulation of stem cells (either from
donor or host) to differentiate into osteoblasts,36,37 for
which vascularization also acts as a key factor for cell sur-
vival. Moreover, although HA/TCP favors MSCs differentia-
tion into osteogenic lineages,38 it has been reported
previously that bare HA/TCP scaffolds fail in inducing bone
formation in both SQ and IM implantation in rats.39 There-
fore, the bare scaffold group was not included in this experi-
mental design.
Yet, bone formation was observed in growth factor-
rather than cell-based constructs. In theory, BMP-2 induces
osteogenic differentiation of resident stem cells and hence
bone formation, but AT-MSCs (either mono- or cocultures)
are expected to improve bone formation, based on their
osteogenic differentiation capacities in vivo. No BMP-2
induced bone formation by resident stem cells is to be
expected for cell-based constructs since either osteogeni-
cally induced AT-MSCs do not produce BMP-240 or the
osteogenic fate of AT-MSCs is not inﬂuenced by BMP-2 both
in vitro and in vivo.41,42 However, bone formation using
human bone marrow MSCs (BM-MSCs) is more frequently
observed because osteogenically differentiated BM-MSCs can
secrete much higher amount of BMP-2 compared with AT-
MSCs.40
Our study further showed that IM implantation did not
enhance bone formation compared with SQ implantation for
growth factor-based scaffolds. The hypothesis that IM
implantation can induce more bone formation was based on
the fact that more pronounced vascularization in IM tis-
sue43,44 can provide more oxygen and nutrition supply for
osteoblastic cells as well as recruitment of more stem cells
from the circulation, and hence enhance bone formation.45
Up to now, bone forming capacity of only rat BM-MSCs
seeded constructs was compared in SQ and IM implantation,
and equal bone formation was observed.33,34 Nevertheless,
it is still unclear for the bone formation in SQ vs. IM when
human AT-MSCs are used since no bone formation was
observed in either of the implantation sites. Moreover, our
study showed that BMP-2 induced similar bone formation at
the two different ectopic implantation sites. This is inconsis-
tent with the previous reports which showed that 5 lg
BMP-2 induced more bone formation in IM compared with
SQ implantation site using collagen gels as a carrier.46,47
Although only one dose of BMP-2 (i.e., 20 lg/construct) was
FIGURE 7. Histological images from methylene blue/basic fuchsin
staining after 8 weeks intramuscular (IM) implantation in vivo (n56).
Bone marrow structures are only observed in the BMP-2 group, which
is also the only group with bone formation. Black arrows indicate
vessel-like structures and white arrows indicate osteocyte-like cells.
Mo, AT-MSCs seeded HA/TCP; Co, AT-MSCs/HUVECs seeded HA/TCP;
BMP-2, BMP-2 loaded HA/TCP. [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
FIGURE 8. Histomorphometrical analysis of bone formation in BMP-2
scaffolds after 8 weeks in vivo implantation (n56). SQ, subcutaneous;
IM, intramuscular; BA, bone area; PA, pore area; ROI, region of inter-
est. [Color figure can be viewed in the online issue, which is available
at wileyonlinelibrary.com.]
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used in this study, it cannot be excluded that different dos-
ages of BMP-2 may inﬂuence bone formation of the two
implantation sites.
Strong arguments exist for the in vivo bone forming
capacity of AT-MSCs, even though their in vitro osteogenic
differentiation capacity has been well established.40,48,49
Using human AT-MSCs, few studies have demonstrated
(effects on) in vivo bone formation, either ectopically49 or
orthotopically,51,52 while others found no bone formation
ectopically53,54 or orthotopically.28 But it is hard to tell the
contribution of the implanted cells to bone formation, espe-
cially at orthotopic implantation sites because the origin of
the formed bone was not identiﬁed. In terms of the failure
in ectopic bone formation using human AT-MSCs, this study
is in accordance with the research from Martin’s group,53,54
in which the tissue-engineered constructs were SQ
implanted for a period of 8 weeks. In one of these two stud-
ies, human AT-MSCs were statically seeded on HA ceramic
scaffolds and implanted in athymic nude mice, without in
vitro preculture in OM.54 In the other, human AT-MSCs were
dynamically (perfusion) seeded and cultured on HA in OM
for 5 days in vitro and subsequently implanted in athymic
nude rats.53 These authors emphasized in a review paper
that two parameters were critically required for induction
of osteogenic potential by AT-MSCs, which are the osteo-
genic commitment of AT-MSCs and the presence of a min-
eral component in the scaffold.49 Although our experimental
design met these two requirements, no bone formation was
found. This suggests that more or other requirements are
needed to obtain in vivo bone formation at ectopic implanta-
tion sites. Although considerably small scaffolds (3 3 3 3 3
mm3) were used, in which vascularization throughout the
scaffolds might be faster in comparison to big scaffolds, no
bone formation was observed in cell-based scaffolds. Never-
theless, it is not possible to dispose the potential for stem
cells by ignoring the carrier selected, indicating perhaps the
performance of the cells compared with the growth factor
suffers from an inherent prejudice in choice of a scaffold. In
this experiment, one type of calcium-phosphate based scaf-
fold (75% HA/25% b-TCP) was chosen. Recent studies have
shown that the bone formation capacity of MSCs is strongly
affected by the calcium-content and formulation of scaf-
folds.55 Additionally, although no statistical analysis was
performed, the porosity from micro-CT analysis demon-
strated a decrease for both Mo and Co constructs after 8
weeks in vivo implantation compared with the original bare
HA/TCP scaffolds, suggesting the formation of radiopaque
tissue in cell-based constructs. Moreover, it has been
reported that HUVECs alone cultured on TCP scaffolds
induced an equal amount of bone formation as that of the
bare TCP scaffolds group, meaning that HUVECs alone have
limited contribution to osteogenesis19 and therefore this
group was not included in our study.
The lack of bone formation in both culture conditions
(Mo and Co) is in contrast with cocultures using BM-MSCs,
in which half of the MSCs in cocultures form even more
bone compared with monocultures.18 Consistently, the in
vitro results also showed the same trend, since ALP-activity
was not enhanced in Co compared to Mo. Despite the obser-
vation of vessel-like structures for both Mo and Co, the
technical challenge to histologically process ceramic-
containing constructs via proper (e.g., parafﬁn) embedding
which is necessary for immunohistochemical staining,
makes it hard to do quantitative analysis of blood vessel for-
mation and determine the origin (either donor or host).
Although the hypothesis that IM implantation induces
more bone formation compared with SQ implantation was
not proved in this study, in both cell-based scaffolds
because of the lack of bone formation and growth factor-
based scaffolds due to the possible dosage effects of BMP-2,
this study gives a hint that more parameters (e.g., growth
factor dosage, scaffold and cell type, cell seeding density)
may inﬂuence the results and thus need to be considered
for such comparison. The clinical relevance of this work
points toward the need for more studies (e.g., the underly-
ing mechanisms and requirements of bone formation) to
justify clinical application of AT-MSCs and AT-MSCs/HUVECs
in the ﬁeld of bone regenerative medicine.
CONCLUSIONS
The results of this study demonstrated that different ectopic
implantation sites did not affect the bone forming capacity
of either cell- or growth factor-based HA/TCP constructs.
Further, bone formation was only observed for growth
factor-based constructs. This study indicates that osteogenic
differentiation capacity of AT-MSCs in vitro does not warrant
in vivo bone formation, necessitating further research on the
activation of cell-based bone formation for cytotherapeutic
treatments.
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